ICI 74,917: a new anti-allergic drug administered by pressurised aerosol.
Ten patients with allergic rhinitis were challenged intranasally with allergen before, and half an hour, 2 hours and 4 hours after intranasal administration of placebo, disodium cromoglycate powder and an aerosol containing ICI 74,917, a new compound with anti-allergic action. ICI 74,917 had a maximum protective effect after half an hour, but was significantly better than placebo 2 hours after nasal use. The effect was significantly better than that of disodium cromoglycate powder. The results will encourage studies of ICI 74,917 in the treatment of allergic rhinitis.
D000336:Aerosols; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000627:therapeutic use; D006801:Humans; D010618:Phenanthrolines / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D013997:Time Factors
D000336:Aerosols; D010618:Phenanthrolines; D010919:Placebos; D004205:Cromolyn Sodium